Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: zurdo who wrote (4378)	7/15/1998 11:02:00 PM
From: BigKNY3	Read Replies (4) \| Respond to of 9523

Listed below are the PFE ratings, 12 month target prices and recent comments from 15 analysts. Please feel free to add to this list using the following format: Broker: Analyst: Date: PFE Rating: Target Price: Comments: Have PFun! BigKNY3 ______________________________________________________ PFE Analyst Roll Call: 7/15/98 Broker: Gruntal & Co. Analyst: David F. Saks Date: 7/10/98 PFE Rating: Strong Buy Target Price: $148 Comments: "Viagra sales will approach $1 billion this year and possibly $8 billion at peak (2005)....PFE just blew us out of the water. .And we haven't seen the impact yet of the international market where Viagra won't be sold for several months." Broker: Salomon Smith Barney Analyst: Christina Heuer Date: 7/10/98 PFE Rating: Buy Target Price: $155 Comments: "Zeldox is not dead yet. But the drug is in limbo until PFE discloses the r results of its pow-wow with FDA. Best case: delayed 6-18 months while PFE generates additional data or re-analyzes current data. Worst case: Zeldox is never approved by FDA." Broker: Gerard Klauer Mattison Analyst: Cynthia A. Beach Date: 7/10/98 PFE Rating: Buy Target Price: $140 : Broker: Warburg Dillon Read Inc Analyst: Jerome R. Brimeyer Date: 7/10/98 PFE Rating: Buy Target Price: $135 Broker: NationsBanc Montgomery Securities Analyst: Leonard S. Yaffe MD Date: 7/10/98 PFE Rating: Buy Target Price: $132 Comments: "The drug of the year is Viagra, but PFE has in hand what should be next year's drug of the year (Celebra). (Earnings) were driven by Viagra, which beat our estimates by a couple of million $." Broker: J.P. Morgan Securities Analyst: Carl J. Seiden Date: 7/10/98 PFE Rating: Buy Target Price: $131 Comments: "PFE is best in industry". Broker: Merrill Lynch Analyst: Steven C. Tighe Date: 7/10/98 PFE Rating: Buy: Near-term and long-term Target Price: Unknown Broker: A.G. Edwards Analyst: Kenneth R. Nover Date: 7/10/98 PFE Rating: Buy Target Price: Unknown Broker: PaineWebber Inc. Analyst: Jeffrey Chaffkin Date: 7/10/98 PFE Rating: Attractive Target Price: $130 Broker: Schroder & Co. Analyst: Jami Rubin Date: 7/10/98 PFE Rating: Outperform Target Price: $130 Broker: Morgan Stanley Dean Witter Analyst: Paul A. Brooke Date: 7/10/98 PFE Rating: Outperform Target Price: $120 Broker: Furman Selz Analyst: James Flynn Date: 7/07/98 PFE Rating: Hold Target Price: Unknown Comments: "Consider our present peak Viagra estimate of $2 billion (2002) to be potentially high". Broker: Brown Brothers Harriman Analyst: Michael Krensavage Date: 7/10/98 PFE Rating: Neutral Target Price: Unknown Comments: "The question is how much reuse will (Viagra) get.The bottom line is that it's a highly effective drug." Broker: HKS & Co Analyst: Hemandt Shah Date: 7/10/98 PFE Rating: Neutral Target Price: Unknown Comments: "PFE is doing well across the board.(Viagra ) had just a phenomenal .performance. Certainly, Viagra will continue to grow. The real question is by how much." Broker: Global Securities Analyst: Marcel Brichon Date: 7/07/98 PFE Rating: Unknown Target Price: Unknown Comments: "PFE's a great hold for all its other products.Once the hesitancy (over Viagra) comes out of the marketplace, I expect strong growth."